Possible participation of pICln in the regulation of angiogenesis through alternative splicing of vascular endothelial growth factor receptor mRNAs

Endothelium: Journal of Endothelial Cell Research

Volumn 11, Issue 5-6, 2004, Pages 293-300

  Li, Hui ^a   Yonekura, Hideto ^a   Kim, Chul Hee ^a   Sakurai, Shigeru ^a   Yamamoto, Yasuhiko ^a   Takiya, Toshiyuki ^b   Futo, Satoshi ^c   Watanabe, Takuo ^a   Yamamoto, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Kanagawa 243 0041   (Japan)

^c FASMAC Co   (Japan)

Author keywords

Alternative splicing; Angiogenesis; Antisense; Endothelial cell; Functional genomics; pICln

Indexed keywords

ANGIOSTATIC PROTEIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENTARY DNA; MESSENGER RNA; NEUROPILIN 1; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CELL GROWTH; CONTROLLED STUDY; ENDOTHELIUM CELL; EXPRESSED SEQUENCE TAG; GENE OVEREXPRESSION; GENETIC SCREENING; HUMAN; HUMAN CELL; MITOSIS INHIBITION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; SEQUENCE DATABASE; SOLUBILITY; VASCULAR ENDOTHELIUM;

ALTERNATIVE SPLICING; ANTISENSE ELEMENTS (GENETICS); HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN ISOFORMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RNA, MESSENGER;

EID: 12344327364     PISSN: 10623329     EISSN: None     Source Type: Journal    
DOI: 10.1080/10623320490904250     Document Type: Article

References (36)

1. Altschul S.F., Gish W., Miller W., Myers E.W., and Lipman D.J. (1990) Basic local alignment search tool. Journal of Molecular Biology, 215, 403-410.
2. Beserga R., and Denhardt D.T. (1992) Antisense Strategies New York Academy of Sciences, New York.
3. Black D.L. (2000) Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology. Cell 103, 367-370.
4. Black D.L. (2003) Mechanisms of alternative pre-messenger RNA splicing. Annual Review in Biochemistry, 72, 291-336.
5. Carmeliet P.(2003) Angiogenesis in health and disease. Nature Medicine, 9, 653-693.
6. Collins F.S., Green E.D., Guttmacher A.E., Guyer M.S., and US National Human Genome Research Institute (2003) A vision for the future of genomics research. Nature, 422, 835-847.
7. Crooke S.T. (1995) Medical Intelligence Unit-Therapeutic Applications of Oligonucleotides. R.G. Landes Company, Texas.
8. de Vries C., Escobedo J.A., Ueno H., Houck K., Ferrara N., and Williams L.T. (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science, 255, 989-991.
9. Friesen W.J., Paushkin S., Wyce A., Massenet S., Pesiridis G.S., Duyne G.V., Rappsilber J., Mann M., and Dreyfuss G. (2001) The methylosome, a 20s complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins. Molecular and Cellular Biology 21, 8289-8300.
10. Gagnon M.L., Bielenberg D.R., Gechtman Z., Miao H., Takashima S., Soker S., and Klagsbrun M. (2000) Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vitro expression and antitumor activity. Proceeding of the National Academy of Sciences of the United States of America, 97, 2573-2578.
11. Good D.J., Polverim P.J., Rastinejad F., Le Beau M.M., Lemons R.S., Frazier W.A., and Bouck N.P. (1990) A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proceeding of the National Academy of Sciences of the United States of America, 87, 6624-6628.
12. Goldman C.K., Kendall RL., Cabrera G., Soroceanu L., Heike Y, Gillespie G.Y., Siegal G.P., Mao X., Bett A.J., Huckle W.R., Thomas K.A., and Curiel D.T. (1998) Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proceeding of the National Academy of Sciences of the United States of America, 95, 8795-800.
13. Graveley B.R. (2001) Alternative splicing: Increasing diversity in the proteomic world. Trends in Genetics, 17, 100-107.
14. Hanahan D., and Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86, 353-364.
15. Hornig C., Barleon B., Ahmad S., Vuorela P., Ahmed A., and Weich H.A. (2000) Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Laboratory Investigation, 80, 443-454.
16. Kaneda Y. (2003) New vector innovation for drug delivery: Development of fusigenic non-viral particles. Current Drug Targets, 4, 599-602.
17. Kendall R.L., and Thomas K.A. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proceeding of the National Academy of Sciences of the United States of America, 90, 10705-10709.
18. Kozak M. (1991) An analysis of vertebrate mRNA sequences: Intimations of translational control. Journal of Cell Biology, 115, 887-903.
19. Kuo C.J., Farnebo F., Yu E.Y., Christofferson R., Swearingen R.A., Carter R., von Recum H.A., Yuan J., Kamihara J., Flynn E., D'Amato R., Folkman J., and Mulligan R.C. (2001) Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proceeding of the National Academy of Sciences of the United States of America, 98, 4605-4610.
20. Maniatis T., and Tasic B. (2002) Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature, 418, 236-243.
21. Mosmann T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
22. Namiki A., Brogi E., Kearney M., Kim E.A., Wu T., Couffinhal T., Varticovski L., and Isner J.M. (1995) Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. Journal of Biological Chemistry, 270, 3118-3115.
23. Nomura M., Yamagishi S., Harada S., Hayashi Y., Yamashima T., Yamashita J., and Yamamoto H. (1995) Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. Journal of Biological Chemistry, 270, 28316-28324.
24. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead JR., Olsen B.R., and Folkman J. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277-285.
25. Palmichi M., Li Y., Wickman K., Petalta E., and Clapham D. (1992) New mammalian chloride channel identified by expression cloning. Nature, 356, 238-241.
26. Pennisi E. (2003) Human genome. Reaching their goal early, sequencing labs celebrate. Science, 300, 409.
27. Pu W.T., Krapivinsky G.B., Krapivinsky L., and Clapham D.E., (1999) pICln inhibits snRNP biogenesis by binding core splicsomal proteins. Molecular and Cellular Biology, 19, 4113-4120.
28. Rossignol M., Gagnon M.L. and Klagsrun M. (2000) Genomic organization of human neuropilin-1 and neuropilin-2 genes: Identification and distribution of splice variants and soluble isoforms. Genomics, 70, 211-222.
29. Snyder M., Gerstein M. (2003) Genomics. Defining genes in the genomics era. Science, 300, 258-260.
30. Soker S., Takashima S., Miao H.Q., Neufeld G., and Klagsbrun M. (1998) Neurophilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745.
31. Wu P., Yonekura H., Li H., Nozaki I., Tomono Y., Naito I., Ninomiya Y., and Yamamoto H. (2001) Hypoxia down-regulates endostatin production by human microvascular endothelial cells and pericytes, Biochemical and Biophysical Research Communications, 288, 1149-1154.
32. Yamagishi S., Yonekura H., Yamamoto Y., Katsuno K., Sato F., Mita I., Ooka H., Satozawa N., Kawakami T., Nomura M., and Yamamoto H. (1997) Advanced glycation end products-driven angiogenesis in vitro Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. Journal of Biological Chemistry, 272, 8723-8730.
33. Yonekura H., Migita H., Sakurai S., Wang H., Harada S., Abedin M.D.J., Yamagishi S, and Yamamoto H. (1999a) Antisense display - a method for functional gene screening: evaluation in a cell-free system and isolation of angiogenesis-related genes. Nucleic Acids Research 27, 2591-2600.
34. Yonekura H., Sakurai S., Liu X., Migita H., Wang H., Yamagishi S., Nomura M., Abedin M.D.J., Unoki H., Yamamoto Y., and Yamamoto, H. (1999b) Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes: implication in autocrine and paracrine regulation of angiogenesis. Journal of Biological Chemistry, 274, 35172-35178.
35. Yonekura H., Yasui K., Sakurai S., Li H., Yamamoto Y., and Yamamoto H. (2001) Antisense display - A new method for functional gene screen and its application to angiogenesis-related gene isolation. Annuals of the New York Academy of Sciences, 947, 382-386.
36. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.D.J., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., and Yamamoto H. (2003) Novel splice variants of the receptor for advanced glycation endproducts (RAGE) expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochemical Journal, 370, 1097-1109.